11月25日，山东省政府新闻办举行新闻发布会，邀请山东省卫生健康委主要负责同志等介绍"十四五"时 期山东全面推进健康山东建设情况。 山东省卫生健康委员会副主任、山东省中医药管理局副局长李明介绍，"十四五"时期，山东聚焦提升中 医药服务能力和水平，高质量建设国家中医药综合改革示范区，实施中医药振兴发展重大工程，加快推 动中医药高质量发展。截至2024年底，全省每千人口公立中医类医院床位数0.78张，每千人口中医执业 （助理）医师数0.8人，中医总诊疗人次1.27亿，较"十三五"末分别增长25.81%、53.85%和103.49%，中 医药传承创新发展跑出"加速度"。 中医医疗资源布局更加优化。获批建设国家中医疫病防治基地、国家中医康复中心各1处、中医类国家 区域医疗中心项目3个，建成省级区域中医医疗中心9家，优质医疗资源进一步扩容。省、市、县均建成 政府办中医类医院，二级以上政府办综合医院、妇幼保健院、传染病医院全部设置中医类临床科室，乡 镇卫生院和社区卫生服务中心中医药综合服务区实现全覆盖，贯通城乡的中医药服务网络越织越密。 中医药服务能力持续增强。创建国家中医优势专科48个，建成齐鲁中医药优势专科集群28个 ...

Core Viewpoint - The Chinese government emphasizes the need to enhance high-quality technological supply and policy support to promote the upgrading of the biopharmaceutical industry, focusing on the development of innovative and effective new drugs to improve public health and well-being [2][4]. Group 1: Industry Development - The biopharmaceutical industry is identified as a strategic emerging industry that is crucial for public health and well-being [7]. - There is a significant market potential in the health industry, with a broad outlook for the development of innovative drugs [4]. - The government aims to strengthen original innovation and tackle key core technologies, leveraging both government and market resources to foster innovation [7]. Group 2: Innovation and Research - The focus is on increasing technological innovation efforts, particularly in new targets, new compounds, and new mechanisms of action [4]. - The government encourages the establishment of collaborative research efforts and the cultivation of high-end talent in the life sciences field [4]. - There is a push for the integration of artificial intelligence to enhance various stages of drug development, clinical trials, diagnosis, treatment, and production [7]. Group 3: Policy Support and Collaboration - The government plans to provide policy support in areas such as talent development and financing to nurture high-quality enterprises [4]. - There is an emphasis on optimizing the operational models of innovation platforms to create replicable and scalable experiences [5]. - The government seeks to enhance the synergy between product research, regulatory approval, and management to improve the application of high-level innovative drugs [7].

Core Insights - The Chinese government emphasizes the importance of the biopharmaceutical industry for enhancing public health and aims to accelerate innovation and development in this sector [2][4]. Group 1: Government Initiatives - The government plans to increase high-quality technological supply and policy support to promote the biopharmaceutical industry's upgrade and innovation [2][4]. - There is a focus on strengthening original innovation and tackling key core technologies, leveraging both government and market resources to achieve breakthroughs [4]. Group 2: Industry Development - The biopharmaceutical market in China is seen as having significant growth potential, with a strong emphasis on developing innovative drugs with high clinical value and transformation potential [3]. - Companies are encouraged to deepen international cooperation and enhance their innovation and competitiveness through policy support in talent and financing [3]. Group 3: Research and Collaboration - The government advocates for collaborative research efforts targeting new drug targets, compounds, and mechanisms, aiming to produce significant original results and cultivate high-end talent in life sciences [2][3]. - There is a push for the establishment of shared research platforms and one-stop R&D solutions to facilitate the integration of medical and engineering fields, as well as industry-academia collaboration [3]. Group 4: Technology Integration - The integration of artificial intelligence in various stages of drug development, clinical trials, and production is highlighted as a means to enhance the industry's development [4]. - The government aims to optimize policies related to drug procurement and negotiation mechanisms to support the application of high-level innovative drugs [4].

Group 1 - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry, focusing on high-quality technological supply and policy support to enhance innovation and produce more effective drugs [1][2] - The government aims to strengthen original innovation and tackle key core technologies, leveraging both government and market resources to foster a collaborative innovation environment [2] - There is a significant market potential for the health industry in China, with a strong emphasis on the development of innovative drugs and the need for timely identification of high clinical value projects [1][2] Group 2 - The government encourages the establishment of comprehensive support systems for biopharmaceutical innovation, including one-stop R&D solutions and collaboration between industry, academia, and research [2] - The integration of artificial intelligence in various stages of drug development, clinical trials, and production is highlighted as a means to enhance industry development [2] - The government also aims to promote the modernization and industrialization of traditional Chinese medicine by applying modern scientific theories and technologies [2]

Core Viewpoint - The article emphasizes the need for high-quality technological supply and policy support to enhance the development of the biopharmaceutical industry in China, focusing on innovation and the production of effective new drugs to improve public health [1][2][3]. Group 1: Government Initiatives - The Chinese government aims to accelerate the biopharmaceutical sector by increasing technological innovation and focusing on new targets, compounds, and mechanisms [1]. - There is a significant market potential for innovative drugs in China's health industry, and the government encourages the identification of high clinical value projects and their integration into medical institutions [2]. - The government plans to enhance original innovation and tackle key technologies by mobilizing resources from both the government and the market [3]. Group 2: Industry Development - The article highlights the importance of creating a supportive environment for biopharmaceutical companies, including talent cultivation and financial support [2]. - It stresses the need for a comprehensive service model that integrates research and development, production, and application to facilitate the commercialization of scientific achievements [2]. - The integration of artificial intelligence in various stages of drug development and production is emphasized to improve efficiency and effectiveness [3]. Group 3: Traditional Medicine - The article calls for the revitalization of traditional Chinese medicine through modern scientific methods, enhancing its theoretical and practical frameworks [3].

Core Viewpoint - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry through enhanced technological innovation and policy support, aiming to improve public health and foster high-quality drug development [1][2]. Group 1: Industry Development - The biopharmaceutical industry is identified as a strategic emerging industry that significantly impacts public health and well-being [2]. - There is a call for increased investment in original innovation and key core technology breakthroughs, leveraging both government and market resources to foster innovation [2]. - The market potential for the health industry is highlighted, with a focus on the promising future of innovative drug development [1]. Group 2: Innovation and Collaboration - The government encourages the establishment of shared research and development platforms to accelerate the transformation of biopharmaceutical innovations into practical applications [2]. - There is an emphasis on the integration of artificial intelligence to enhance various stages of drug development, clinical trials, and production processes [2]. - The importance of fostering high-quality enterprises through policy support in talent and financing is stressed, alongside promoting international collaboration [1]. Group 3: Policy and Regulatory Framework - The need for improved coordination in product research, evaluation, and management policies is highlighted to optimize drug procurement and negotiation mechanisms [2]. - The government aims to enhance guidance on the application of high-level innovative drugs, ensuring a supportive regulatory environment for the biopharmaceutical sector [2]. - There is a focus on modernizing and industrializing traditional Chinese medicine by applying modern scientific theories and technologies [2].

Core Viewpoint - The company is preparing for its 2024 Annual Shareholders' Meeting, focusing on governance, strategic development, and financial performance, while ensuring shareholder rights and compliance with regulations [1][2][3]. Meeting Agenda - The meeting is scheduled for June 20, 2025, at 10:00 AM, in Kunming, Yunnan Province, with the chairman Wu Wendo presiding [3][4]. - Key agenda items include the 2024 Annual Board Work Report, Annual Supervisory Board Work Report, Annual Financial Settlement Report, and Profit Distribution Proposal [3][4][5]. Governance and Compliance - The company emphasizes the importance of maintaining order and efficiency during the meeting, with strict adherence to legal and procedural requirements [1][2]. - The board is committed to protecting shareholder rights and ensuring compliance with the Company Law and Securities Law [1][2]. Strategic Development - The board has developed a five-year strategic plan (2024-2028) focusing on becoming a leader in the silver-haired health industry and premium traditional Chinese medicine [11][12]. - The company aims to enhance its core business areas, particularly in chronic disease management and the traditional Chinese medicine sector [11][12]. Financial Performance - The company reported a net profit of 648.08 million yuan for the year, a year-on-year increase of 19.86%, and a net profit excluding non-recurring items of 419.21 million yuan, up 25.09% [17]. - A cash dividend of 0.20 yuan per share (including tax) is proposed, totaling approximately 151.42 million yuan [12][31]. Risk Management - The board is focused on enhancing risk management frameworks and internal controls to identify and mitigate potential risks [15][16]. - Regular audits and compliance checks are conducted to ensure adherence to legal and regulatory standards [15][16]. Investor Relations - The company is committed to improving information disclosure quality and maintaining effective communication with investors [18][19]. - It has received recognition for its investor relations efforts, including an A-level rating for information disclosure from the Shanghai Stock Exchange [19].